World's First Genetically Recombinant Collagenase
Therapeutics (CNT201) Begins Clinical Trials in Australia
SEOUL,
South Korea, July 30,
2024 /PRNewswire/ -- Connext has announced the
successful first administration of CNT201, its therapeutic
treatment for Dupuytren's contracture, in patients.
Dupuytren's contracture is a debilitating condition
characterized by the fibrosis of the fascia between the skin and
tendons of the palm due to collagen buildup, causing fingers to
become permanently bent and significantly impairing patients'
quality of life. Currently, there is no fundamental cure for this
condition. Treatments primarily involve surgical interventions like
fasciectomy to alleviate symptoms, although non-surgical methods,
such as localized injections of collagenase, have shown high
patient satisfaction.
It has received IND approval for Phase 1/2 clinical trials from
the U.S. FDA and recently completed the Clinical Trial Notification
(CTN) process in Australia. The
ongoing clinical trial in Australia represents the Phase 1 part of the
Phase 1/2 trial, conducted across three hospitals. The trial
involves single administrations of four escalating dose levels in
patients with Dupuytren's contracture, followed by a four-week
evaluation period to assess safety, tolerability, efficacy,
pharmacokinetics, and immunogenicity. Connext plans to secure
proof-of-concept (PoC) data by mid-next year and determine the
optimal dose for Phase 2, with the aim to commence the Phase 2
trial in the latter half of the year.
Connext CEO Woojong Lee remarked,
"This first administration marks a significant milestone, offering
new hope to patients suffering from Dupuytren's contracture. We are
dedicated to developing a safer and more effective treatment to
improve their quality of life."
Connext successfully raised a Series B investment at the end of
last year and was selected for the Scale-Up TIPS program, enabling
the initiation of global clinical trials for Dupuytren's
contracture. The company is simultaneously advancing the
development of additional indications, including Peyronie's disease
and cellulite.
Media Contact:
Sangho Lee(Communication)
+82-10-8829-4694
Sangho.lee@connext.co.kr
View original
content:https://www.prnewswire.com/news-releases/connext-successfully-administers-first-dose-of-cnt201-for-dupuytrens-contracture-302208354.html
SOURCE Connext